NCT03006003

Brief Summary

The study will be conducted to assess the depressive symptoms and related markers in the postmenopausal female after anti-osteoporosis treatment.

Trial Health

43
At Risk

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Trial has exceeded expected completion date
Enrollment
500

participants targeted

Target at P75+ for phase_4

Timeline
Completed

Started Jan 2017

Longer than P75 for phase_4

Geographic Reach
1 country

2 active sites

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

First Submitted

Initial submission to the registry

December 16, 2016

Completed
14 days until next milestone

First Posted

Study publicly available on registry

December 30, 2016

Completed
2 days until next milestone

Study Start

First participant enrolled

January 1, 2017

Completed
4.9 years until next milestone

Primary Completion

Last participant's last visit for primary outcome

December 1, 2021

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

December 1, 2021

Completed
Last Updated

January 14, 2019

Status Verified

January 1, 2018

Enrollment Period

4.9 years

First QC Date

December 16, 2016

Last Update Submit

January 11, 2019

Conditions

Keywords

OsteoporosisRaloxifeneCentral nervous disorders

Outcome Measures

Primary Outcomes (1)

  • Brain-derived neurotrophic factor

    Serum brain-derived neurotrophic factor (BDNF) Levels

    3 months

Secondary Outcomes (10)

  • Brain-derived neurotrophic factor

    1 year

  • Vascular cell adhesion molecule-1

    3 months

  • Orexin-A

    3 months

  • Body components

    3 months

  • Zung self-rating depression scale

    3 months

  • +5 more secondary outcomes

Study Arms (3)

Raloxifene group

EXPERIMENTAL

Raloxifene treatment

Drug: Raloxifene

Comparator group

ACTIVE COMPARATOR

Alendronate treatment

Drug: Alendronate

Control group

NO INTERVENTION

To refuse anti-osteoporosis treatment

Interventions

Raloxifene tratment more than 4 weeks

Also known as: Evista
Raloxifene group

Alendronic acid 70mg with Colecalciferol 70mcg

Also known as: FOSAMAX PLUS
Comparator group

Eligibility Criteria

Age20 Years+
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Postmenopausal female
  • Osteoporosis

You may not qualify if:

  • Psychological disorders

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (2)

outpatient clinic of the Division of Endocrinology and Metabolism in Taichung Veterans General Hospital

Taichung, 407, Taiwan

RECRUITING

Taichung Veterans General Hospital

Taichung, 407, Taiwan

RECRUITING

MeSH Terms

Conditions

Depressive DisorderOsteoporosis

Interventions

Raloxifene HydrochlorideAlendronate

Condition Hierarchy (Ancestors)

Mood DisordersMental DisordersBone Diseases, MetabolicBone DiseasesMusculoskeletal DiseasesMetabolic DiseasesNutritional and Metabolic Diseases

Intervention Hierarchy (Ancestors)

TamoxifenStilbenesBenzylidene CompoundsBenzene DerivativesHydrocarbons, AromaticHydrocarbons, CyclicHydrocarbonsOrganic ChemicalsDiphosphonatesOrganophosphonatesOrganophosphorus Compounds

Central Study Contacts

I-Te Lee, MD, PhD

CONTACT

I-Te Lee, MD, PhD

CONTACT

Study Design

Study Type
interventional
Phase
phase 4
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
SPONSOR

Study Record Dates

First Submitted

December 16, 2016

First Posted

December 30, 2016

Study Start

January 1, 2017

Primary Completion

December 1, 2021

Study Completion

December 1, 2021

Last Updated

January 14, 2019

Record last verified: 2018-01

Data Sharing

IPD Sharing
Will not share

Locations